Telix Pharmaceuticals has completed enrolment in its pivotal BiPASS trial, moving the Australian company closer to testing whether its gallium-based PSMA PET imaging agents can help determine which men with suspected prostate cancer need a biopsy in the first place. …
Telix completes BiPASS enrolment as it pursues a broader role for PSMA PET
September 2, 2026 Australian Biotech
Latest Video
New Stories
-
ENA Respiratory secures funding to test antiviral nasal spray in people with asthma
September 2, 2026 - -
OncoSil pursues a reimbursement pathway as it prepares for US rollout
September 2, 2026 - - Australian Biotech -
Vitrafy takes its cryopreservation technology into the US cell therapy market
September 2, 2026 - - Australian Biotech -
Telix completes BiPASS enrolment as it pursues a broader role for PSMA PET
September 2, 2026 - - Australian Biotech -
Roche maps a new chapter with move to new Sydney CBD location
September 2, 2026 - - Latest News -
Priceline Pharmacy broadens women’s health support with new parenting program
September 2, 2026 - -
The non-disclosure agreement is just about creating a zone of controlled silence
September 2, 2026 -